SAN DIEGO, Nov. 3, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit
Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 11, 2015 at 4:00 p.m. ET/2:00 p.m.
MT/1:00 p.m. PT. Dr.
Helen Torley, president and CEO,
will provide a corporate overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at www.halozyme.com, and a
recording will be made available for 90 days following the event.
To access the live webcast, please log on to Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, metastatic breast
cancer and has potential across additional cancers in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug
delivery platform, ENHANZE™, which enables biologics and small
molecule compounds that are currently administered intravenously to
be delivered subcutaneously. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-credit-suisse-healthcare-conference-300171474.html
SOURCE Halozyme Therapeutics, Inc.